Dr. James Schreppler Chiropractor Medicare: Medicare Enrolled Practice Location: 213 Washington St., Millsboro, DE 19966 Phone: 302-934-7711 |
Apple Chiropractic, Inc. Chiropractor - Occupational Health Medicare: Not Enrolled in Medicare Practice Location: 31507 Oak Orchard Rd., Ste. 12, Millsboro, DE 19969 Phone: 302-644-4920 |
Auto Injury And Rehabilitation Center, Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 98 Rudder Rd, Unit, Millsboro, DE 19966 Phone: 302-945-1910 Fax: 302-945-1910 |
Dr. Christopher William Baldt, DC Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 98 Rudder Road, Unit 1, Millsboro, DE 19966 Phone: 302-945-4575 Fax: 302-945-1910 |
Long Neck Chiropractic Health Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 32783 Long Neck Rd Unit 1, Millsboro, DE 19966 Phone: 302-945-4575 Fax: 888-945-8260 |
Dr. Randal L. Horsley, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 28253 Dupont Blvd, Unit 1, Millsboro, DE 19966 Phone: 302-934-7350 Fax: 302-934-7319 |
Coastal Chiropractic, Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 28467 Dupont Blvd, Unit 1, Millsboro, DE 19966 Phone: 302-933-0700 Fax: 302-933-0800 |
Long Neck Chiropractic, Inc. Chiropractor Medicare: Medicare Enrolled Practice Location: 98 Rudder Rd, Unit 1, Millsboro, DE 19966 Phone: 302-945-4575 Fax: 302-945-1910 |
News Archive
Vitrolife AB: Fourth quarter - Sales increased by 19 percent in local currency. Sales were the highest ever for a single quarter and amounted to SEK 95 (81) million, corresponding to an increase of 18 percent in SEK.
The results of a study presented today at the Annual European Congress of Rheumatology 2017 have confirmed that Fluorescence Optical Imaging, a technique used to visualize inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis.
4SC AG, the German drug discovery and development company, today announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer.
Today the U.S. Food and Drug Administration proposed the Innovation Pathway, a priority review program for new, breakthrough medical devices and announced the first submission: a brain-controlled, upper-extremity prosthetic that will serve as a pilot for the program. The FDA also announced plans to seek further public comment before the Pathway can be used more broadly.
Elevated or diminished eye pressure impairs our ability to see, and in the worst cases, can even lead to blindness. Until now, there has been no effective long-term treatment. In response, Fraunhofer researchers are developing an implantable microfluid system that can efficiently and durably stabilize intraocular pressure.
› Verified 7 days ago